BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17:2427-2443. [PMID: 20217257 DOI: 10.1245/s10434-010-1006-3] [Cited by in Crossref: 220] [Cited by in F6Publishing: 204] [Article Influence: 18.3] [Reference Citation Analysis]
Number Citing Articles
1 Qi S, Huang M, Teng H, Lu Y, Jiang M, Wang L, Shi J, Ma Q, Gu G, Xin Y, Ma H. Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer. Tumor Biol 2015;36:9979-85. [DOI: 10.1007/s13277-015-3794-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
2 Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D, Kountourakis P. Chromogranin A as a valid marker in oncology: Clinical application or false hopes? World J Methodol 2017; 7(1): 9-15 [PMID: 28396845 DOI: 10.5662/wjm.v7.i1.9] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
3 Dammen R, Haugen M, Svejda B, Alaimo D, Brenna O, Pfragner R, Gustafsson BI, Kidd M. The stimulatory adenosine receptor ADORA2B regulates serotonin (5-HT) synthesis and release in oxygen-depleted EC cells in inflammatory bowel disease. PLoS One. 2013;8:e62607. [PMID: 23638125 DOI: 10.1371/journal.pone.0062607] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
4 Dörffel Y, Swidsinski A, Loening-baucke V, Wiedenmann B, Pavel M. Common biostructure of the colonic microbiota in neuroendocrine tumors and Crohnʼs disease and the effect of therapy: . Inflammatory Bowel Diseases 2012;18:1663-71. [DOI: 10.1002/ibd.21923] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
5 Walter T, Chardon L, Chopin-laly X, Raverot V, Caffin AG, Chayvialle JA, Scoazec JY, Lombard-Bohas C. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer. 2012;48:1766-1773. [PMID: 22133573 DOI: 10.1016/j.ejca.2011.11.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
6 Goetz TI, Lang EW, Prante O, Maier A, Cordes M, Kuwert T, Ritt P, Schmidkonz C. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent 177Lu-DOTATOC therapy. Ann Nucl Med 2020;34:244-53. [PMID: 32114682 DOI: 10.1007/s12149-020-01440-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Korse C, Taal B, Bonfrer J, Vincent A, van Velthuysen M, Baas P. An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival. Annals of Oncology 2011;22:2625-30. [DOI: 10.1093/annonc/mdr007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
8 Kövesdi A, Kurucz PA, Nyírő G, Darvasi O, Patócs A, Butz H. Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2488. [PMID: 32887459 DOI: 10.3390/cancers12092488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Daskalakis K, Norlén O, Hellman P, Stålberg P. Applying the use of novel biomarkers for neuroendocrine tumors in the clinic: where are we now? International Journal of Endocrine Oncology 2019;6:IJE14. [DOI: 10.2217/ije-2017-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Ku JW, Zhang DY, Song X, Li XM, Zhao XK, Lv S, Hu SJ, Cheng R, Zhou FY, Wu HF, Wang LD. Characterization of tissue chromogranin A (CgA) immunostaining and clinicohistopathological changes for the 125 Chinese patients with primary small cell carcinoma of the esophagus.Dis Esophagus. 2017;30:1-7. [PMID: 28575250 DOI: 10.1093/dote/dox041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
11 Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A, Ferone D, Florio T. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discovery Today 2014;19:458-68. [DOI: 10.1016/j.drudis.2013.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
12 Heiskala K, Andersson LC. Reg IV is differently expressed in enteroendocrine cells of human small intestine and colon. Regul Pept. 2013;183:27-34. [PMID: 23499801 DOI: 10.1016/j.regpep.2013.03.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Herrera-Martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocr Relat Cancer 2019;26:R157-79. [PMID: 30615596 DOI: 10.1530/ERC-18-0354] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
14 Andreasi V, Partelli S, Manzoni M, Muffatti F, Colombo B, Corti A, Falconi M. Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). Pancreatology 2019;19:57-63. [DOI: 10.1016/j.pan.2018.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Shanahan MA, Salem A, Fisher A, Cho CS, Leverson G, Winslow ER, Weber SM. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. Journal of Surgical Research 2016;201:38-43. [DOI: 10.1016/j.jss.2015.10.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
16 van der Knaap RHP, Kwekkeboom DJ, Ramakers CRB, de Rijke YB. Evaluation of a new immunoassay for chromogranin A measurement on the Kryptor system. Pract Lab Med 2015;1:5-11. [PMID: 28932793 DOI: 10.1016/j.plabm.2015.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
17 Shiba S, Morizane C, Hiraoka N, Sasaki M, Koga F, Sakamoto Y, Kondo S, Ueno H, Ikeda M, Yamada T. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. Pancreatology. 2016;16:99-105. [PMID: 26718527 DOI: 10.1016/j.pan.2015.11.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
18 Singh S, Dey C, Kennecke H, Kocha W, Maroun J, Metrakos P, Mukhtar T, Pasieka J, Rayson D, Rowsell C. Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Ann Surg Oncol. 2015;22:2685-2699. [PMID: 25366583 DOI: 10.1245/s10434-014-4145-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
19 Miyazaki K, Orton MR, Davidson RL, d’Arcy JA, Lewington V, Koh TS, Thng CH, Leach MO, Collins DJ, Koh DM. Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. Radiology. 2012;263:139-148. [PMID: 22344403 DOI: 10.1148/radiol.12110770] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
20 Buikhuisen WA, Theresia Tesselaar ME, van Velthuysen MF, Korse CM, Taal BG, Baas P. Neuroendocrine tumors of the lung: a comprehensive overview. International Journal of Endocrine Oncology 2014;1:71-9. [DOI: 10.2217/ije.14.4] [Reference Citation Analysis]
21 Zhang D, Babayan L, Ho H, Heaney AP. Chromogranin A regulates neuroblastoma proliferation and phenotype. Biol Open 2019;8:bio036566. [PMID: 30833285 DOI: 10.1242/bio.036566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Cui T, Hurtig M, Elgue G, Li SC, Veronesi G, Essaghir A, Demoulin JB, Pelosi G, Alimohammadi M, Öberg K, Giandomenico V. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS One 2010;5:e16010. [PMID: 21209860 DOI: 10.1371/journal.pone.0016010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
23 van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Kema IP, Koopmans KP, Valk GD, Timmers HJ, de Herder WW, Feelders RA, Fockens P, Sluiter WJ, de Vries EG, Links TP. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointestinal Endoscopy 2015;81:159-167.e2. [DOI: 10.1016/j.gie.2014.09.037] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
24 Halfdanarson TR, Howe JR, Haraldsdottir S, O'dorisio TM. Circulating tumor markers in patients with neuroendocrine tumors – a clinical perspective. International Journal of Endocrine Oncology 2015;2:89-99. [DOI: 10.2217/ije.14.38] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Singh S, Law C. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Review of Gastroenterology & Hepatology 2014;6:313-34. [DOI: 10.1586/egh.12.15] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
26 Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K, Liu Y, Venzon D, Turkbey I, Choyke P, Yao J, Libutti SK, Nilubol N, Linehan WM, Kebebew E. Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome. J Am Coll Surg. 2014;218:163-169. [PMID: 24440063 DOI: 10.1016/j.jamcollsurg.2013.10.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
27 Kaifi JT, Kayser G, Ruf J, Passlick B. The Diagnosis and Treatment of Bronchopulmonary Carcinoid. Dtsch Arztebl Int 2015;112:479-85. [PMID: 26214234 DOI: 10.3238/arztebl.2015.0479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
28 Yun SP, Shin N, Seo HI. Clinical outcomes of small cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder. World J Gastroenterol 2015; 21(1): 269-275 [PMID: 25574101 DOI: 10.3748/wjg.v21.i1.269] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
29 Shariati A, Fallah F, Pormohammad A, Taghipour A, Safari H, Chirani AS, Sabour S, Alizadeh-Sani M, Azimi T. The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome. J Cell Physiol 2019;234:8550-69. [PMID: 30480810 DOI: 10.1002/jcp.27828] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
30 Mateo J, Heymach JV, Zurita AJ. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Mol Diagn Ther 2012;16:151-61. [PMID: 22515658 DOI: 10.2165/11632590-000000000-00000] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
31 Schimmack S, Lawrence B, Svejda B, Alaimo D, Schmitz-Winnenthal H, Fischer L, Büchler MW, Kidd M, Modlin I. The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms. Cancer 2012;118:2763-75. [PMID: 21990041 DOI: 10.1002/cncr.26592] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gautam P, Nair SC, Gupta MK, Sharma R, Polisetty RV, Uppin MS, Sundaram C, Puligopu AK, Ankathi P, Purohit AK, Chandak GR, Harsha HC, Sirdeshmukh R. Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS One 2012;7:e46153. [PMID: 23029420 DOI: 10.1371/journal.pone.0046153] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
33 Shi H, Jiang C, Zhang Q, Qi C, Yao H, Lin R. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm. Diagn Pathol 2020;15:108. [PMID: 32917216 DOI: 10.1186/s13000-020-01030-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Mateo J, Heymach JV, Zurita AJ. Circulating Biomarkers of Response to Sunitinib in Gastroenteropancreatic Neuroendocrine Tumors: Current Data and Clinical Outlook. Mol Diagn Ther 2012;16:151-61. [DOI: 10.1007/bf03262203] [Cited by in Crossref: 10] [Article Influence: 1.0] [Reference Citation Analysis]
35 Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 2013;31:1265-74. [PMID: 23269537 DOI: 10.1007/s10637-012-9910-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
36 Han X, Zhang C, Tang M, Xu X, Liu L, Ji Y, Pan B, Lou W. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. European Journal of Gastroenterology & Hepatology 2015;27:527-35. [DOI: 10.1097/meg.0000000000000332] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
37 Tőke J, Czirják G, Tóth M, Rácz K, Patócs A. Significance of biochemical markers in the diagnosis of neuroendocrine tumours and in the follow-up of patients. Orvosi Hetilap 2014;155:1775-82. [DOI: 10.1556/oh.2014.30035] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Effraimidis G, Knigge U, Rossing M, Oturai P, Rasmussen ÅK, Feldt-Rasmussen U. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin Cancer Biol 2021:S1044-579X(21)00112-7. [PMID: 33905872 DOI: 10.1016/j.semcancer.2021.04.011] [Reference Citation Analysis]
39 Shim JR, Kim JR, Park Y, Seo HI. Small-cell neuroendocrine carcinoma arising from an extra-hepatic bile duct: a case report. Gastroenterol Rep (Oxf) 2021;9:380-2. [PMID: 34567573 DOI: 10.1093/gastro/goaa051] [Reference Citation Analysis]
40 Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocrine-Related Cancer 2018;25:R11-29. [DOI: 10.1530/erc-17-0269] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
41 Gerber DE, Paik PK, Dowlati A. Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies. Am Soc Clin Oncol Educ Book 2015;:147-62. [PMID: 25993153 DOI: 10.14694/EdBook_AM.2015.35.147] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
42 Ramachandran R, Bech P, Murphy KG, Dhillo WS, Meeran KM, Chapman RS, Caplin M, Ghatei MA, Bloom SR, Martin NM. Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays. Clin Endocrinol (Oxf) 2012;76:831-6. [PMID: 22175276 DOI: 10.1111/j.1365-2265.2011.04319.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
43 Filosso PL, Kidd M, Roffinella M, Lewczuk A, Chung K, Kolasinska-cwikla A, Cwikla J, Lowczak A, Doboszynska A, Malczewska A, Catalano M, Zunino V, Boita M, Arvat E, Cristofori R, Guerrera F, Oliaro A, Tesselaar M, Buikhuisen W, Kos-kudla B, Papotti M, Bodei L, Drozdov I, Modlin I. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression†. European Journal of Cardio-Thoracic Surgery 2018;53:631-9. [DOI: 10.1093/ejcts/ezx386] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
44 Al-Efraij K, Aljama MA, Kennecke HF. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med 2015;4:864-70. [PMID: 25727756 DOI: 10.1002/cam4.435] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
45 Raoof M, Jutric Z, Melstrom LG, Lee B, Li D, Warner SG, Fong Y, Singh G. Prognostic significance of Chromogranin A in small pancreatic neuroendocrine tumors. Surgery 2019;165:760-6. [PMID: 30447803 DOI: 10.1016/j.surg.2018.10.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
46 Fottner C, Ferrata M, Weber MM. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose? Rev Endocr Metab Disord. 2017;18:393-410. [PMID: 29256148 DOI: 10.1007/s11154-017-9438-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
47 Yazdanpanah O, Surapaneni S, Shanah L, Kabashneh S. Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review. Cureus 2021;13:e14006. [PMID: 33884247 DOI: 10.7759/cureus.14006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Huang YQ. Recent advances in understanding pancreatic endocrine tumors. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1541-1549 [DOI: 10.11569/wcjd.v19.i15.1541] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Mpilla GB, Philip PA, El-Rayes B, Azmi AS. Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. World J Gastroenterol 2020; 26(28): 4036-4054 [PMID: 32821069 DOI: 10.3748/wjg.v26.i28.4036] [Reference Citation Analysis]
50 Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro. Anticancer Drugs 2013;24:66-72. [PMID: 23147412 DOI: 10.1097/CAD.0b013e3283584f75] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
51 Jang S, Janssen A, Aburjania Z, Robers MB, Harrison A, Dammalapati A, Cheng YQ, Chen H, Jaskula-Sztul R. Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo. Oncotarget 2017;8:70828-40. [PMID: 29050323 DOI: 10.18632/oncotarget.19993] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
52 Sahani DV, Bonaffini PA, Fernández-Del Castillo C, Blake MA. Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management. Radiology 2013;266:38-61. [PMID: 23264526 DOI: 10.1148/radiol.12112512] [Cited by in Crossref: 95] [Cited by in F6Publishing: 68] [Article Influence: 10.6] [Reference Citation Analysis]
53 Ambrosini V, Campana D, Nanni C, Cambioli S, Tomassetti P, Rubello D, Fanti S. Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour? Eur J Nucl Med Mol Imaging 2012;39:1278-83. [PMID: 22584487 DOI: 10.1007/s00259-012-2146-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
54 Rocca C, Grande F, Granieri MC, Colombo B, De Bartolo A, Giordano F, Rago V, Amodio N, Tota B, Cerra MC, Rizzuti B, Corti A, Angelone T, Pasqua T. The chromogranin A1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1. Acta Physiol (Oxf) 2021;231:e13570. [PMID: 33073482 DOI: 10.1111/apha.13570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Woltering EA, Voros BA, Beyer DT, Thiagarajan R, Ramirez RA, Mamikunian G, Boudreaux JP. Plasma Pancreastatin Predicts the Outcome of Surgical Cytoreduction in Neuroendocrine Tumors of the Small Bowel. Pancreas 2019;48:356-62. [PMID: 30768573 DOI: 10.1097/MPA.0000000000001263] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Lackermair K, Clauss S, Voigt T, Klier I, Summo C, Hildebrand B, Nickel T, Estner HL, Kääb S, Wakili R, Wilbert-Lampen U. Alteration of Endothelin 1, MCP-1 and Chromogranin A in patients with atrial fibrillation undergoing pulmonary vein isolation. PLoS One 2017;12:e0184337. [PMID: 28886122 DOI: 10.1371/journal.pone.0184337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
57 Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World J Gastroenterol 2015; 21(32): 9512-9525 [PMID: 26327759 DOI: 10.3748/wjg.v21.i32.9512] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
58 Wang Y, Huang K, Chen J, Luo Y, Zhang Y, Jia Y, Xu L, Chen M, Huang B, Ni D, Li ZP, Feng ST. Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis. Contrast Media Mol Imaging 2018;2018:6037273. [PMID: 30510495 DOI: 10.1155/2018/6037273] [Reference Citation Analysis]
59 Chiloiro S, Lanza F, Bianchi A, Schinzari G, Brizi MG, Giampietro A, Rufini V, Inzani F, Giordano A, Rindi G, Pontecorvi A, De Marinis L. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study. Endocrine 2018;60:362-7. [PMID: 28567607 DOI: 10.1007/s12020-017-1327-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
60 Dlugosz A, Zakikhany K, Muschiol S, Hultenby K, Lindberg G. Infection of human enteroendocrine cells with Chlamydia trachomatis: a possible model for pathogenesis in irritable bowel syndrome. Neurogastroenterol Motil 2011;23:928-34. [PMID: 21883697 DOI: 10.1111/j.1365-2982.2011.01765.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
61 Michael M, Garcia-Carbonero R, Weber MM, Lombard-Bohas C, Toumpanakis C, Hicks RJ. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist 2017;22:272-85. [PMID: 28220021 DOI: 10.1634/theoncologist.2016-0305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
62 Popovici T, Moreira B, Schlageter M, Bories P. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A. Clinical Biochemistry 2014;47:87-91. [DOI: 10.1016/j.clinbiochem.2013.10.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
63 Korse CM, Buning-kager JC, Linders TC, Heijboer AC, van den Broek D, Tesselaar ME, van Tellingen O, van Rossum HH. A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients. Clinica Chimica Acta 2017;469:130-5. [DOI: 10.1016/j.cca.2017.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
64 Jun E, Kim SC, Song KB, Hwang DW, Lee JH, Shin SH, Hong SM, Park K, Lee Y. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute. Surgery 2017;162:120-30. [DOI: 10.1016/j.surg.2017.01.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
65 Halperin DM, Kulke MH. Management of Pancreatic Neuroendocrine Tumors. Gastroenterology Clinics of North America 2012;41:119-31. [DOI: 10.1016/j.gtc.2011.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
66 Gorelik M, Ahmad M, Grossman D, Grossman M, Cooperman AM. Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors. Surgical Clinics of North America 2018;98:157-67. [DOI: 10.1016/j.suc.2017.09.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
67 Borazan E, Aytekin A, Yilmaz L, Elci M, Karaca MS, Kervancioglu S, Balik AA. Multifocal Insulinoma in Pancreas and Effect of Intraoperative Ultrasonography. Case Rep Surg 2015;2015:375124. [PMID: 26295000 DOI: 10.1155/2015/375124] [Reference Citation Analysis]
68 Zou J, Li Q, Kou F, Zhu Y, Lu M, Li J, Lu Z, Shen L. Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours. Curr Oncol. 2019;26:e30-e38. [PMID: 30853807 DOI: 10.3747/co.26.4135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
69 Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Beuschlein F, Wängler B, Uebleis C, Schmidt GP, Spitzweg C, Bartenstein P. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology. 2014;270:517-525. [PMID: 24056402 DOI: 10.1148/radiol.13122501] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
70 Ito T, Igarashi H, Jensen RT. Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas 2012;41:505-7. [PMID: 22504376 DOI: 10.1097/MPA.0b013e318249a92a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
71 Zhang C, Huang Y, Long J, Yao X, Wang J, Zang S, Qu W, Wang F. Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression. Oncol Lett 2019;17:1497-504. [PMID: 30675205 DOI: 10.3892/ol.2018.9795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirády P, Oláh C, Széll T, Csizmarik A, Hadaschik B, Reis H. High-soluble CGA levels are associated with poor survival in bladder cancer. Endocr Connect 2019;8:625-33. [PMID: 30999279 DOI: 10.1530/EC-19-0068] [Reference Citation Analysis]
73 Ramírez-Rentería C, Ferreira-Hermosillo A, Marrero-Rodríguez D, Taniguchi-Ponciano K, Melgar-Manzanilla V, Mercado M. An Update on Gastroenteropancreatic Neuroendocrine Neoplasms: From Mysteries to Paradigm Shifts. Arch Med Res 2020;51:765-76. [PMID: 32654882 DOI: 10.1016/j.arcmed.2020.06.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Sharma J, Duque M, Saif MW. Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians. Therap Adv Gastroenterol 2013;6:474-90. [PMID: 24179483 DOI: 10.1177/1756283X13498808] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
75 Tian T, Gao J, Li N, Li Y, Lu M, Li Z, Lu Z, Li J, Shen L. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors. PLoS One 2016;11:e0154679. [PMID: 27159453 DOI: 10.1371/journal.pone.0154679] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
76 Zhang DY, Huang GR, Ku JW, Zhao XK, Song X, Xu RH, Han WL, Zhou FY, Wang R, Wei MX, Wang LD. Development and validation of a prognostic nomogram model for Chinese patients with primary small cell carcinoma of the esophagus. World J Clin Cases 2021; 9(30): 9011-9022 [PMID: 34786384 DOI: 10.12998/wjcc.v9.i30.9011] [Reference Citation Analysis]
77 Monaghan P, Lamarca A, Valle J, Hubner R, Mansoor W, Trainer P, Darby D. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours. Clin Endocrinol 2016;84:348-52. [DOI: 10.1111/cen.12985] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
78 Lv Y, Han X, Zhang C, Fang Y, Pu N, Ji Y, Wang D, Xuefeng X, Lou W. Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs. Endocr Connect. 2018;7:169-178. [PMID: 29191920 DOI: 10.1530/ec-17-0276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
79 Keutgen XM, Hammel P, Choyke PL, Libutti SK, Jonasch E, Kebebew E. Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease. Nat Rev Clin Oncol 2016;13:537-49. [DOI: 10.1038/nrclinonc.2016.37] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
80 Fuksiewicz M, Kowalska M, Kolasińska-Ćwikła A, Ćwikła JB, Sawicki Ł, Roszkowska-Purska K, Drygiel J, Kotowicz B. Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine. Endocr Connect 2018;7:803-10. [PMID: 29724794 DOI: 10.1530/EC-18-0059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
81 Tomita T. Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors. Bosn J Basic Med Sci 2020;20:336-46. [PMID: 32020844 DOI: 10.17305/bjbms.2020.4632] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
82 Konsek-Komorowska SJ, Pęczkowska M, Kolasińska-Ćwikła AD, Konka M, Chrapowicki E, Ćwikła JB. Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome. Med Clin (Barc) 2021:S0025-7753(21)00515-7. [PMID: 34736622 DOI: 10.1016/j.medcli.2021.06.029] [Reference Citation Analysis]
83 Jeune F, Taibi A, Gaujoux S. Update on the Surgical Treatment of Pancreatic Neuroendocrine Tumors. Scand J Surg. 2020;109:42-52. [PMID: 31975647 DOI: 10.1177/1457496919900417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
84 Patel D, Chan D, Cehic G, Pavlakis N, Price TJ. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Rev Endocrinol Metab 2016;11:311-27. [PMID: 30058926 DOI: 10.1080/17446651.2016.1199952] [Reference Citation Analysis]
85 Lee DW, Kim MK, Kim HG. Diagnosis of Pancreatic Neuroendocrine Tumors. Clin Endosc. 2017;50:537-545. [PMID: 29207856 DOI: 10.5946/ce.2017.131] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
86 Vaghaiwalla T, Keutgen XM. Surgical Management of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:243-52. [PMID: 32151358 DOI: 10.1016/j.soc.2019.11.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
87 Eissa N, Hussein H, Kermarrec L, Ali AY, Marshall A, Metz-Boutigue MH, Hendy GN, Bernstein CN, Ghia JE. Chromogranin-A Regulates Macrophage Function and the Apoptotic Pathway in Murine DSS colitis. J Mol Med (Berl) 2018;96:183-98. [PMID: 29274006 DOI: 10.1007/s00109-017-1613-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
88 Shah D, Lamarca A, Valle JW, McNamara MG. The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms. J Clin Med 2021;10:403. [PMID: 33494364 DOI: 10.3390/jcm10030403] [Reference Citation Analysis]
89 Bourebaba Y, Mularczyk M, Marycz K, Bourebaba L. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome. Biomed Pharmacother 2021;134:111113. [PMID: 33341043 DOI: 10.1016/j.biopha.2020.111113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
90 Mula-Abed WA, Ahmed R, Ramadhan FA, Al-Kindi MK, Al-Busaidi NB, Al-Muslahi HN, Al-Lamki MA. A Rare Case of Adrenal Pheochromocytoma with Unusual Clinical and Biochemical Presentation: 
A Case Report and Literature Review. Oman Med J 2015;30:382-90. [PMID: 26421121 DOI: 10.5001/omj.2015.76] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Ezzat S. PANCREATIC INCIDENTALOMAS: IS IT NET OR NOT? Endocr Pract 2016;22:895-6. [PMID: 26919655 DOI: 10.4158/EP161238.CO] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
92 Kidd M, Bodei L, Modlin IM. Chromogranin A: any relevance in neuroendocrine tumors? Curr Opin Endocrinol Diabetes Obes 2016;23:28-37. [PMID: 26627724 DOI: 10.1097/MED.0000000000000215] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
93 Adu-Gyamfi KO, Gyamfi R, Patri S. An unusual case of proton pump inhibitor induced hyperchromograninemia. J Community Hosp Intern Med Perspect 2019;9:511-4. [PMID: 32002161 DOI: 10.1080/20009666.2019.1682748] [Reference Citation Analysis]
94 Modlin IM, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab. 2016;30:59-77. [PMID: 26971844 DOI: 10.1016/j.beem.2016.01.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
95 Nölting S, Kuttner A, Lauseker M, Vogeser M, Haug A, Herrmann KA, Hoffmann JN, Spitzweg C, Göke B, Auernhammer CJ. Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers (Basel) 2012;4:141-55. [PMID: 24213232 DOI: 10.3390/cancers4010141] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
96 Pulvirenti A, Rao D, Mcintyre CA, Gonen M, Tang LH, Klimstra DS, Fleisher M, Ramanathan LV, Reidy-Lagunes D, Allen PJ. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford). 2019;21:612-618. [PMID: 30366884 DOI: 10.1016/j.hpb.2018.09.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
97 Öberg K. Neuroendocrine gastro-enteropancreatic tumors - from eminence based to evidence-based medicine - A Scandinavian view. Scand J Gastroenterol 2015;50:727-39. [PMID: 25855088 DOI: 10.3109/00365521.2015.1033001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
98 Yu F, Fu J, Zhang C, Wu W, Ai S, Yao X, Meng Q, Huang Y, Lu G, Wang F, Qu W. Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms. Pancreas 2021;50:882-9. [PMID: 34347728 DOI: 10.1097/MPA.0000000000001852] [Reference Citation Analysis]
99 Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017;189:E398-404. [PMID: 28385820 DOI: 10.1503/cmaj.160771] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
100 Martins D, Spada F, Lambrescu I, Rubino M, Cella C, Gibelli B, Grana C, Ribero D, Bertani E, Ravizza D, Bonomo G, Funicelli L, Pisa E, Zerini D, Fazio N; IEO ENETS Center of Excellence for GEP NETs. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. Target Oncol 2017;12:611-22. [PMID: 28634872 DOI: 10.1007/s11523-017-0506-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
101 Zuber S, Wesley R, Prodanov T, Eisenhofer G, Pacak K, Kantorovich V. Clinical utility of chromogranin A in SDHx-related paragangliomas. Eur J Clin Invest 2014;44:365-71. [PMID: 24467715 DOI: 10.1111/eci.12245] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
102 Rossi RE, Ciafardini C, Sciola V, Conte D, Massironi S. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis. Pancreas 2018;47:1249-55. [PMID: 30325865 DOI: 10.1097/MPA.0000000000001184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
103 Xu X, Honda K, Miura N, Hori S, Le Blanc S, Bergmann F, Gaida MM, Volkmar M, Schimmack S, Hackert T, Strobel O, Felix K. Actinin-4 splice variant - a complementary diagnostic and prognostic marker of pancreatic neuroendocrine neoplasms. J Cancer 2020;11:2318-28. [PMID: 32127958 DOI: 10.7150/jca.37503] [Reference Citation Analysis]
104 Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol 2017;28:1309-15. [PMID: 28327907 DOI: 10.1093/annonc/mdx078] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
105 Jeske W, Glinicki P, Kapuścińska R. Commentary to "chromogranin a: biological function and clinical utility in neuroendocrine tumor disease". Ann Surg Oncol 2011;18:293. [PMID: 20549561 DOI: 10.1245/s10434-010-1146-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
106 Zhang K, Lehner LJ, Praeger D, Baumann G, Knebel F, Quinkler M, Roepke TK. Glucagonoma-induced acute heart failure. Endocrinol Diabetes Metab Case Rep 2014;2014:140061. [PMID: 25520848 DOI: 10.1530/EDM-14-0061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
107 Appetecchia M, Lauretta R, Rota F, Carlini M. Neuroendocrine Tumors Biomarkers. In: Carlini M, editor. Abdominal Neuroendocrine Tumors. Milano: Springer Milan; 2018. pp. 65-78. [DOI: 10.1007/978-88-470-3955-1_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Wang YH, Yang QC, Lin Y, Xue L, Chen MH, Chen J. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine (Baltimore). 2014;93:e247. [PMID: 25501094 DOI: 10.1097/md.0000000000000247] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
109 Canakis A, Lee LS. Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Endosc 2022; 14(5): 267-290 [DOI: 10.4253/wjge.v14.i5.267] [Reference Citation Analysis]
110 Landry CS, Cavaness K, Celinski S, Preskitt J. Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors. Gland Surg 2014;3:215-8. [PMID: 25493250 DOI: 10.3978/j.issn.2227-684X.2014.10.01] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
111 Chatani PD, Agarwal SK, Sadowski SM. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2020;11:575620. [PMID: 33537001 DOI: 10.3389/fendo.2020.575620] [Reference Citation Analysis]
112 Ito T, Hijioka S, Masui T, Kasajima A, Nakamoto Y, Kobayashi N, Komoto I, Hijioka M, Lee L, Igarashi H, Jensen RT, Imamura M. Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. J Gastroenterol 2017;52:9-18. [PMID: 27539256 DOI: 10.1007/s00535-016-1250-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
113 Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM, Kidd M. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy. J Clin Endocrinol Metab 2015;100:E1437-45. [PMID: 26348352 DOI: 10.1210/jc.2015-2792] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
114 Bílek R, Vlček P, Šafařík L, Michalský D, Novák K, Dušková J, Václavíková E, Widimský J Jr, Zelinka T. Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers (Basel) 2019;11:E586. [PMID: 31027285 DOI: 10.3390/cancers11040586] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
115 Rehfeld JF. Chromogranin A in gastrinomas: Promises and pitfalls. Clin Chim Acta 2015;446:15-20. [PMID: 25861845 DOI: 10.1016/j.cca.2015.03.039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Rustagi S, Warner RR, Divino CM. Serum pancreastatin: the next predictive neuroendocrine tumor marker. J Surg Oncol. 2013;108:126-128. [PMID: 23775817 DOI: 10.1002/jso.23359] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
117 Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A; Pancreatic Manifestations Recommendations Development Subcommittee of the VHL Alliance. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Cancer 2021. [PMID: 34735022 DOI: 10.1002/cncr.33978] [Reference Citation Analysis]
118 Schimmack S, Taylor A, Lawrence B, Alaimo D, Schmitz-Winnenthal H, Büchler MW, Modlin IM, Kidd M. A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases. Epigenetics Chromatin 2014;7:15. [PMID: 25071868 DOI: 10.1186/1756-8935-7-15] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
119 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
120 Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol. 2015;110:1223-1232. [PMID: 26032155 DOI: 10.1038/ajg.2015.160] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
121 Shaib WL, Zakka K, Penley M, Jiang R, Akce M, Wu C, Maithel SK, Sarmiento JM, Kooby D, Behera M, Alese OB, El-Rayes BF. Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas 2021;50:1382-91. [PMID: 35041337 DOI: 10.1097/MPA.0000000000001936] [Reference Citation Analysis]
122 Modlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S, Kidd M. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg. 2011;396:1145-1156. [PMID: 21523447 DOI: 10.1007/s00423-011-0794-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
123 Faria SC, Sagebiel T, Patnana M, Cox V, Viswanathan C, Lall C, Qayyum A, Bhosale PR. Tumor markers: myths and facts unfolded. Abdom Radiol (NY) 2019;44:1575-600. [PMID: 30498924 DOI: 10.1007/s00261-018-1845-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
124 Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, Mayer K, Biersack HJ, Ezziddin S. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42:1238-1246. [PMID: 25808630 DOI: 10.1007/s00259-015-3041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Matar S, Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk-Myślicka A, Filosso PL, Suarez AL, Kolasińska-Ćwikła A, Roffinella M, Kos-Kudła B, Ćwikła JB, Drozdov IA, Kidd M, Modlin IM. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms. Neuroendocrinology 2020;110:185-97. [PMID: 30995665 DOI: 10.1159/000500202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
126 Weisbrod AB, Zhang L, Jain M, Barak S, Quezado MM, Kebebew E. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors. Horm Cancer. 2013;4:165-175. [PMID: 23361940 DOI: 10.1007/s12672-013-0134-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
127 Vetter E, Kronast M, Tölge M, Zimmermann W. Lgr5-expressing stem cells are not the cells of origin of pyloric neuroendocrine carcinomas in mice. J Pathol 2016;238:42-51. [PMID: 26333534 DOI: 10.1002/path.4629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
128 Qiu W, Christakis I, Silva A, Bassett RL Jr, Cao L, Meng QH, Gardner Grubbs E, Zhao H, Yao JC, Lee JE, Perrier ND. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol (Oxf) 2016;85:400-7. [PMID: 27256431 DOI: 10.1111/cen.13119] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
129 Tseng CM, Cheng TY, Chen TB, Tien YW, Chen CC, Lin JT, Wang HP. Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors. Oncol Lett 2018;15:8951-8. [PMID: 29805630 DOI: 10.3892/ol.2018.8472] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
130 Puranik AD, Dromain C, Fleshner N, Sathekge M, Pavel M, Eberhardt N, Zengerling F, Marienfeld R, Grunert M, Prasad V. Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. Cancers (Basel) 2021;13:3607. [PMID: 34298822 DOI: 10.3390/cancers13143607] [Reference Citation Analysis]
131 Maggio I, Mollica V, Brighi N, Lamberti G, Manuzzi L, Ricci AD, Campana D. The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest 2020;43:139-48. [DOI: 10.1007/s40618-019-01091-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
132 Kim HK, Bae WK, Choi YD, Shim HJ, Yoon JH, Kang H. Serum Calcitonin May Falsely Estimate Tumor Burden in Chronic Hypercalcemia: A Case of Prostatic and Multiple Bone Metastases from Medullary Thyroid Cancer. Thyroid 2014;24:599-603. [DOI: 10.1089/thy.2013.0121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
133 Filosso PL, Guerrera F, Thomas P, Brunelli A, Lim E, Garcia-yuste M, Asamura H, Papagiannopoulos K, Sarkaria I, Venuta F; The European Society of Thoracic Surgeons Neuroendocrine Tumors of the Lung Working Group. Management of bronchial carcinoids: international practice survey among the European Society of Thoracic Surgeons. Future Oncology 2016;12:1985-99. [DOI: 10.2217/fon-2016-0092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
134 Pusceddu S, Femia D, Lo Russo G, Ortolani S, Milione M, Maccauro M, Vernieri C, Prinzi N, Concas L, Leuzzi L, De Braud F, Buzzoni R. Update on medical treatment of small intestinal neuroendocrine tumors. Expert Rev Anticancer Ther. 2016;16:969-976. [PMID: 27353232 DOI: 10.1080/14737140.2016.1207534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
135 Laskaratos FM, Liu M, Malczewska A, Ogunbiyi O, Watkins J, Luong TV, Mandair D, Caplin M, Toumpanakis C. Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection. Endocrine 2020;69:430-40. [PMID: 32291735 DOI: 10.1007/s12020-020-02289-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012;26:791-802. [PMID: 23582919 DOI: 10.1016/j.bpg.2012.12.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 6.3] [Reference Citation Analysis]
137 Gut P, Czarnywojtek A, Fischbach J, Bączyk M, Ziemnicka K, Wrotkowska E, Gryczyńska M, Ruchała M. Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci 2016;12:1-9. [PMID: 26925113 DOI: 10.5114/aoms.2016.57577] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
138 Korse CM, Muller M, Taal BG. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer 2011;105:1173-5. [PMID: 21989216 DOI: 10.1038/bjc.2011.380] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
139 Kaiserova M, Chudackova M, Mensikova K, Vastik M, Kurcova S, Prikrylova Vranova H, Stejskal D, Kanovsky P. Cerebrospinal Fluid Levels of Chromogranin A in Parkinson's Disease and Multiple System Atrophy. Brain Sci 2021;11:141. [PMID: 33499181 DOI: 10.3390/brainsci11020141] [Reference Citation Analysis]
140 Giovinazzo F, Schimmack S, Svejda B, Alaimo D, Pfragner R, Modlin I, Kidd M. Chromogranin A and its fragments as regulators of small intestinal neuroendocrine neoplasm proliferation. PLoS One 2013;8:e81111. [PMID: 24260544 DOI: 10.1371/journal.pone.0081111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
141 Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 2011;18:S17-25. [DOI: 10.1530/erc-10-0280] [Cited by in Crossref: 61] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
142 Lyubimova NV, Churikova TK, Kushlinskii NE. Chromogranin As a Biochemical Marker of Neuroendocrine Tumors. Bull Exp Biol Med 2016;160:702-4. [PMID: 27021085 DOI: 10.1007/s10517-016-3254-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
143 Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16:e435-e446. [PMID: 26370353 DOI: 10.1016/s1470-2045(15)00186-2] [Cited by in Crossref: 129] [Cited by in F6Publishing: 66] [Article Influence: 18.4] [Reference Citation Analysis]
144 Ku JW, Zhang DY, Song X, Li XM, Zhao XK, Lv S, Hu SJ, Cheng R, Zhou F, Wu HF, Wang LD. Characterization of tissue chromogranin A (CgA) immunostaining and clinicohistopathological changes for the 125 Chinese patients with primary small cell carcinoma of the esophagus. Diseases of the Esophagus 2017;30:1-7. [DOI: 10.1093/dote/dox041] [Reference Citation Analysis]
145 Korse CM, Taal BG, Vincent A, van Velthuysen ML, Baas P, Buning-Kager JC, Linders TC, Bonfrer JM. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer. 2012;48:662-671. [PMID: 21945100 DOI: 10.1016/j.ejca.2011.08.012] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
146 Modlin IM, Drozdov I, Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One. 2013;8:e63364. [PMID: 23691035 DOI: 10.1371/journal.pone.0063364] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 9.4] [Reference Citation Analysis]
147 d'Herbomez M, Bauters C, Cortet-Rudelli C, Dewailly D, Docao C, Wémeau JL. [Biomarkers in endocrinology]. Presse Med 2014;43:40-56. [PMID: 24342177 DOI: 10.1016/j.lpm.2013.11.003] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
148 Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Angelini F, Baldelli R, Berretti D, Bianchetti S, Bizzarri G, Caputo M, Castello R, Cremonini N, Crescenzi A, Davì MV, D'Elia AV, Faggiano A, Pizzolitto S, Versari A, Zini M, Rindi G, Oberg K. Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 2014;37:875-909. [PMID: 25038902 DOI: 10.1007/s40618-014-0119-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
149 Fujimori N, Osoegawa T, Lee L, Tachibana Y, Aso A, Kubo H, Kawabe K, Igarashi H, Nakamura K, Oda Y, Ito T. Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors. Scand J Gastroenterol 2016;51:245-52. [PMID: 26513346 DOI: 10.3109/00365521.2015.1083050] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 6.9] [Reference Citation Analysis]
150 Lamberti G, Brighi N, Campana D. Chromogranin A usefulness in small non-functioning pancreatic neuroendocrine tumors surgical management. Surgery 2019;166:952. [PMID: 30683505 DOI: 10.1016/j.surg.2018.12.004] [Reference Citation Analysis]
151 Zhuge X, Guo C, Chen Y, Feng L, Jia R, Zhao Y, Sun K, Wang Z, Chen X. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma. Pancreas 2018;47:1290-5. [DOI: 10.1097/mpa.0000000000001181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Oberg K. Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics (Sao Paulo) 2012;67 Suppl 1:109-12. [PMID: 22584714 DOI: 10.6061/clinics/2012(sup01)18] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
153 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
154 Bowden M, Zhou CW, Zhang S, Brais L, Rossi A, Naudin L, Thiagalingam A, Sicinska E, Kulke MH. Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma. Oncotarget 2017;8:54331-44. [PMID: 28903345 DOI: 10.18632/oncotarget.16908] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
155 Rossi RE, Garcia-Hernandez J, Meyer T, Thirlwell C, Watkins J, Martin NG, Caplin ME, Toumpanakis C. Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Ann Transl Med. 2015;3:118. [PMID: 26207246 DOI: 10.3978/j.issn.2305-5839.2015.04.23] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
156 Choi YJ, Roh J, Kim S, Lee KA, Park Y. Performance Evaluation of the KRYPTOR Compact PLUS Analyzer-Based B.R.A.H.M.S. CgA Ⅱ KRYPTOR Assay for Chromogranin A Measurement. Diagnostics (Basel) 2021;11:2400. [PMID: 34943638 DOI: 10.3390/diagnostics11122400] [Reference Citation Analysis]
157 Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R;  Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8-21. [PMID: 24384494 DOI: 10.1016/s1470-2045(13)70362-0] [Cited by in Crossref: 256] [Cited by in F6Publishing: 109] [Article Influence: 32.0] [Reference Citation Analysis]
158 Askew JW, Connolly HM. Carcinoid valve disease. Curr Treat Options Cardiovasc Med 2013;15:544-55. [PMID: 23955119 DOI: 10.1007/s11936-013-0265-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
159 Zandee WT, van Adrichem RC, Kamp K, Feelders RA, van Velthuysen MF, de Herder WW. Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Clin Endocrinol 2017;87:165-70. [DOI: 10.1111/cen.13364] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
160 Hijioka M, Ito T, Igarashi H, Fujimori N, Lee L, Nakamura T, Jensen RT, Takayanagi R. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci. 2014;105:1464-1471. [PMID: 25220535 DOI: 10.1111/cas.12533] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
161 Nanno Y, Toyama H, Matsumoto I, Otani K, Asari S, Goto T, Ajiki T, Zen Y, Fukumoto T, Ku Y. Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: A potential predictor of postoperative recurrence. Pancreatology 2017;17:291-4. [PMID: 28043759 DOI: 10.1016/j.pan.2016.12.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
162 Vannella L, Sbrozzi-Vanni A, Lahner E, Bordi C, Pilozzi E, Corleto VD, Osborn JF, Delle Fave G, Annibale B. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011;33:1361-1369. [PMID: 21492197 DOI: 10.1111/j.1365-2036.2011.04659.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
163 Weber DM, Yang JY, Goldman SM, Clarke NJ, Taylor SW, McPhaul MJ. Antibody-Free Quantification of Serum Chromogranin A by Targeted Mass Spectrometry. Clin Chem 2021;67:1618-27. [PMID: 34718463 DOI: 10.1093/clinchem/hvab191] [Reference Citation Analysis]
164 Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 2020;65:18-29. [PMID: 31841822 DOI: 10.1016/j.advms.2019.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
165 Zandee WT, Kamp K, van Adrichem RCS, Feelders RA, de Herder WW. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. European Journal of Endocrinology 2016;175:361-6. [DOI: 10.1530/eje-16-0392] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
166 de Mestier L, Dromain C, d'Assignies G, Scoazec J, Lassau N, Lebtahi R, Brixi H, Mitry E, Guimbaud R, Courbon F, d'Herbomez M, Cadiot G. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocrine-Related Cancer 2014;21:R105-20. [DOI: 10.1530/erc-13-0365] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
167 Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157-176. [PMID: 22262022 DOI: 10.1159/000335597] [Cited by in Crossref: 525] [Cited by in F6Publishing: 425] [Article Influence: 52.5] [Reference Citation Analysis]
168 Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103:153-171. [PMID: 26742109 DOI: 10.1159/000443171] [Cited by in Crossref: 531] [Cited by in F6Publishing: 458] [Article Influence: 88.5] [Reference Citation Analysis]
169 van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Koopmans KP, Kema IP, Zonnenberg BA, Timmers HJ, de Herder WW, Sluiter WJ, de Vries EG, Links TP. Potential value of EUS in pancreatic surveillance of VHL patients. Eur J Endocrinol 2016;174:611-20. [PMID: 26884551 DOI: 10.1530/EJE-15-1012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Di Giacinto P, Rota F, Rizza L, Campana D, Isidori A, Lania A, Lenzi A, Zuppi P, Baldelli R. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. Int J Endocrinol 2018;2018:8126087. [PMID: 30057604 DOI: 10.1155/2018/8126087] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
171 Noor M, Huber AR, Cates JMM, Gonzalez RS. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation. Histopathology 2021;79:416-26. [PMID: 33754384 DOI: 10.1111/his.14369] [Reference Citation Analysis]
172 Lim M, Erdman P, Cho S, Mathew A, Fleisher M, Thoren KL. Evaluation of CisBio ELISA for Chromogranin A Measurement. J Appl Lab Med 2019;4:11-8. [PMID: 31639703 DOI: 10.1373/jalm.2018.028027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Modlin IM, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei L, Kidd M. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr Relat Cancer. 2014;21:615-628. [PMID: 25015994 DOI: 10.1530/erc-14-0190] [Cited by in Crossref: 63] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
174 Milione M, Seregni E. 4. Pathological Diagnosis and Tumor Markers. Tumori 2010;96:810-6. [DOI: 10.1177/030089161009600533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
175 Liu X, Li Y, He L, Feng Y, Tan H, Chen X, Yang W. Simultaneous detection of multiple neuroendocrine tumor markers in patient serum with an ultrasensitive and antifouling electrochemical immunosensor. Biosens Bioelectron 2021;194:113603. [PMID: 34474281 DOI: 10.1016/j.bios.2021.113603] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Zakka K, Nagy R, Drusbosky L, Akce M, Wu C, Alese OB, El-Rayes BF, Kasi PM, Mody K, Starr J, Shaib WL. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. Oncotarget 2020;11:1749-57. [PMID: 32477464 DOI: 10.18632/oncotarget.27588] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
177 Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). Exp Ther Med 2021;22:1479. [PMID: 34765020 DOI: 10.3892/etm.2021.10914] [Reference Citation Analysis]
178 Ganeshan D, Bhosale P, Yang T, Kundra V. Imaging features of carcinoid tumors of the gastrointestinal tract. AJR Am J Roentgenol. 2013;201:773-786. [PMID: 24059366 DOI: 10.2214/ajr.12.9758] [Cited by in Crossref: 43] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
179 Modlin IM, Kidd M, Malczewska A, Drozdov I, Bodei L, Matar S, Chung KM. The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors. Endocrinol Metab Clin North Am 2018;47:485-504. [PMID: 30098712 DOI: 10.1016/j.ecl.2018.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
180 Haugen M, Dammen R, Svejda B, Gustafsson BI, Pfragner R, Modlin I, Kidd M. Differential signal pathway activation and 5-HT function: the role of gut enterochromaffin cells as oxygen sensors. Am J Physiol Gastrointest Liver Physiol 2012;303:G1164-73. [PMID: 22936271 DOI: 10.1152/ajpgi.00027.2012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
181 Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, Tomaszuk M, Kołodziej M, Mikołajczak R, Pawlak D, Hubalewska-Dydejczyk A. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging 2011;38:1669-74. [PMID: 21559978 DOI: 10.1007/s00259-011-1835-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
182 Kulkarni HR, Baum RP. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy. PET Clin 2014;9:91-7. [PMID: 25029938 DOI: 10.1016/j.cpet.2013.08.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
183 Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses MA. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer. 2014;111:1772-1779. [PMID: 25137018 DOI: 10.1038/bjc.2014.462] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
184 Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]
185 Haug AR, Cindea-drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, Schmidt GP, Göke B, Bartenstein P, Hacker M. The Role of 68 Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors. J Nucl Med 2012;53:1686-92. [DOI: 10.2967/jnumed.111.101675] [Cited by in Crossref: 100] [Cited by in F6Publishing: 76] [Article Influence: 10.0] [Reference Citation Analysis]
186 Basuroy R, Sarker D, Quaglia A, Srirajaskanthan R, Ramage J. Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream? International Journal of Endocrine Oncology 2015;2:201-15. [DOI: 10.2217/ije.15.9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
187 Chan DT, Luk AO, So WY, Kong AP, Chow FC, Ma RC, Lo AW. Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis. BMC Endocr Disord. 2016;16:12. [PMID: 26911576 DOI: 10.1186/s12902-016-0087-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
188 Frilling A, Akerström G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012;19:R163-R185. [PMID: 22645227 DOI: 10.1530/erc-12-0024] [Cited by in Crossref: 82] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
189 Georgantzi K, Sköldenberg EG, Stridsberg M, Kogner P, Jakobson Å, Janson ET, Christofferson RHB. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors. Pediatr Hematol Oncol 2018;35:156-65. [PMID: 29737901 DOI: 10.1080/08880018.2018.1464087] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
190 Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 2016;5:174-87. [PMID: 27582247 DOI: 10.1530/EC-16-0043] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 8.2] [Reference Citation Analysis]
191 Mirkin KA, Hollenbeak CS, Wong J. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm. Journal of Surgical Research 2017;211:206-14. [DOI: 10.1016/j.jss.2016.12.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
192 Corsello A, Di Filippo L, Massironi S, Sileo F, Dolcetta Capuzzo A, Gemma M, Carlucci C, Cusini C, Colombo B, Dallatomasina A, Franchi GM, Corti A, Manzoni MF. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. PLoS One. 2018;13:e0196858. [PMID: 29723285 DOI: 10.1371/journal.pone.0196858] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
193 Zatelli MC, Fanciulli G, Malandrino P, Ramundo V, Faggiano A, Colao A; NIKE Group. Predictive factors of response to mTOR inhibitors in neuroendocrine tumours. Endocr Relat Cancer 2016;23:R173-83. [PMID: 26666705 DOI: 10.1530/ERC-15-0413] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
194 Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013;31:365-372. [PMID: 23248251 DOI: 10.1200/jco.2012.44.2905] [Cited by in Crossref: 100] [Cited by in F6Publishing: 49] [Article Influence: 10.0] [Reference Citation Analysis]
195 Hicks RJ. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging 2010;10 Spec no A:S83-91. [PMID: 20880795 DOI: 10.1102/1470-7330.2010.9007] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
196 Miki M, Ito T, Hijioka M, Lee L, Yasunaga K, Ueda K, Fujiyama T, Tachibana Y, Kawabe K, Jensen RT, Ogawa Y. Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors. Jpn J Clin Oncol 2017;47:520-8. [PMID: 28334992 DOI: 10.1093/jjco/hyx032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
197 Tran CG, Sherman SK, Scott AT, Ear PH, Chandrasekharan C, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:732-41. [PMID: 32656719 DOI: 10.1245/s10434-020-08784-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
198 González-Chávez MA, Villegas-Tovar E, González Hermosillo-Cornejo D, Gutierrez-Ocampo A, López-Rangel JA, Athié-Athié AJ. [Neuroendocrine small-cell carcinoma of the gallbladder. An unexpected finding after diagnostic laparoscopy]. Cir Cir 2017;85:168-74. [PMID: 26920213 DOI: 10.1016/j.circir.2015.12.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
199 Zeng YJ, Lai W, Wu H, Liu L, Xu HY, Wang J, Chu ZH. Neuroendocrine-like cells -derived CXCL10 and CXCL11 induce the infiltration of tumor-associated macrophage leading to the poor prognosis of colorectal cancer. Oncotarget. 2016;7:27394-27407. [PMID: 27034164 DOI: 10.18632/oncotarget.8423] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
200 Sharma P, Arora S, Mukherjee A, Pal S, Sahni P, Garg P, Khadgawat R, Thulkar S, Bal C, Kumar R. Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified? Clin Nucl Med 2014;39:37-43. [PMID: 24152621 DOI: 10.1097/RLU.0000000000000257] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
201 Schartinger VH, Falkeis C, Laimer K, Sprinzl GM, Riechelmann H, Rasse M, Virgolini I, Dudás J. Neuroendocrine differentiation in head and neck squamous cell carcinoma. J Laryngol Otol 2012;126:1261-70. [PMID: 23050666 DOI: 10.1017/S0022215112002265] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
202 Tsang VH, Tacon LJ, Learoyd DL, Robinson BG. Pheochromocytomas in Multiple Endocrine Neoplasia Type 2. Recent Results Cancer Res 2015;204:157-78. [PMID: 26494388 DOI: 10.1007/978-3-319-22542-5_7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
203 Joshi H, Vastrad B, Vastrad C. Identification of Important Invasion-Related Genes in Non-functional Pituitary Adenomas. J Mol Neurosci 2019;68:565-89. [PMID: 30982163 DOI: 10.1007/s12031-019-01318-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
204 Mendelson AH, Donowitz M. Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.Dig Dis Sci. 2017;62:2258-2265. [PMID: 28776139 DOI: 10.1007/s10620-017-4695-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
205 Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, Appetecchia M. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers (Basel) 2019;11:E1113. [PMID: 31382663 DOI: 10.3390/cancers11081113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
206 Rayes N, Denecke T. [Gastroenteropancreatic neuroendocrine tumors]. Radiologe 2021. [PMID: 34727206 DOI: 10.1007/s00117-021-00929-w] [Reference Citation Analysis]
207 Ito T, Cadiot G, Jensen RT. Diagnosis of Zollinger-Ellison syndrome: Increasingly difficult. World J Gastroenterol 2012; 18(39): 5495-5503 [PMID: 23112541 DOI: 10.3748/wjg.v18.i39.5495] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
208 Yang J, Roy R, Jedinak A, Moses MA. Mining the Human Proteome: Biomarker Discovery for Human Cancer and Metastases. Cancer J 2015;21:327-36. [PMID: 26222086 DOI: 10.1097/PPO.0000000000000139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
209 Pregun I, Herszényi L, Juhász M, Miheller P, Hritz I, Patócs A, Rácz K, Tulassay Z. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011;84:22-8. [PMID: 21304238 DOI: 10.1159/000321535] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
210 Aluri V, Dillon JS. Biochemical Testing in Neuroendocrine Tumors. Endocrinol Metab Clin North Am 2017;46:669-77. [PMID: 28760232 DOI: 10.1016/j.ecl.2017.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
211 Kidd M, Modlin IM, Bodei L, Drozdov I. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. Cell Mol Gastroenterol Hepatol 2015;1:131-53. [PMID: 28210673 DOI: 10.1016/j.jcmgh.2014.12.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
212 Dillon JS. Workup of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:165-83. [PMID: 32151354 DOI: 10.1016/j.soc.2019.10.002] [Reference Citation Analysis]
213 Wojcik E, Kulpa JK. Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response. Lung Cancer (Auckl) 2017;8:231-40. [PMID: 29238236 DOI: 10.2147/LCTT.S149516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
214 Khagi S, Saif MW. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease. Curr Opin Oncol. 2015;27:38-43. [PMID: 25390554 DOI: 10.1097/cco.0000000000000146] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
215 Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, Wang YH, Chen J, Lu CM. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 2014;14:64. [PMID: 25099181 DOI: 10.1186/1472-6823-14-64] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
216 Mandair D, Khan MS, Lopes A, Furtado O’mahony L, Ensell L, Lowe H, Hartley JA, Toumpanakis C, Caplin M, Meyer T. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism 2021;106:872-82. [DOI: 10.1210/clinem/dgaa822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
217 Campana D, Ravizza D, Ferolla P, Faggiano A, Grimaldi F, Albertelli M, Ricci C, Santini D, Brighi N, Fazio N, Colao A, Ferone D, Tomassetti P. Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine. 2017;56:633-638. [PMID: 27592118 DOI: 10.1007/s12020-016-1099-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
218 Luo G, Jin K, Cheng H, Liu C, Guo M, Lu Y, Yang C, Xu J, Wang W, Gao H. Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncol Lett. 2017;14:6795-6800. [PMID: 29163700 DOI: 10.3892/ol.2017.7071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]